Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Up 725.0% in January

Synaptogenix, Inc. (NASDAQ:SNPX) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 19,800 shares, a growth of 725.0% from the December 31st total of 2,400 shares. Based on an average daily trading volume, of 26,400 shares, the short-interest ratio is presently 0.8 days. Currently, 1.5% of the shares of the company are sold short.

Synaptogenix Stock Up 1.4 %

Synaptogenix stock traded up $0.05 during mid-day trading on Tuesday, reaching $3.56. The company’s stock had a trading volume of 14,906 shares, compared to its average volume of 23,928. Synaptogenix has a 12-month low of $2.32 and a 12-month high of $7.22. The firm’s fifty day moving average price is $3.11 and its two-hundred day moving average price is $3.31.

Synaptogenix (NASDAQ:SNPX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($4.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.95) by ($2.63).

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.